DLL3 and small cell lung carcinoma: Four independent studies were published in the Journal of Thoracic Oncology in 2021, namely MERU (Rova-T versus placebo as a maintenance treatment in patients with SCLC after platinum-based chemotherapy regardless of DLL3 expression) [46], TAHOE (Rova-T versus topotecan as second-line therapy in high DLL3 expression SCLC) [47], and two phase I/II trials [48,49].